Background: Osteonecrosis of the hips and knees is an often debilitating adverse event in children treated with glucocorticoids for leukemia and lymphoma but the impact of shoulder involvement has been understudied. Thus, we investigated the severity and functional impairment of shoulder osteonecrosis in a well-characterized population of pediatric patients treated for acute lymphoblastic leukemia or lymphoma. Methods: We retrospectively reviewed orthopaedic clinic and physical therapy evaluations to determine range of motion (ROM), pain, and impact of magnetic resonance-defined osteonecrosis (ON) on activities of daily living. Adverse events were classified according to the National Cancer Institute's Common Terminology Criteria for Adverse Events version 4.03. Results: We identified 35 patients (22 female), median age at cancer diagnosis 14.2 (range, 4.3 to 19) years; median age at ON diagnosis 16.7 (range, 5.5 to 28) years. Median time to last follow-up from diagnosis of primary malignancy was 6.4 (range, 0 to 12.7) years and from diagnosis of ON was 4.0 (range, 0 to 8.9) years. Twenty-two patients had magnetic resonance evidence of ON; 43 shoulders involved at least 30% of the articular surface of the capital humeral epiphyses. Common Terminology Criteria for Adverse Events mean scores for initial assessments of 55 shoulders (29 patients) showed moderate negative impact of ON on activity of daily living (1.94), decreased ROM limiting athletic activity (0.98), and mild to moderate levels of pain (1.38). Analysis of this group's most recent assessment showed improvement in pain and ON over time, with an average pain grade of 0.58 indicating no pain to mild pain, and 1.37 for ON grade, indicating asymptomatic to mildly symptomatic impact on activities of daily living. We also found minimal worsening average ROM grades (1.11).
G lucocorticoid-induced osteonecrosis is a known toxicity in pediatric and young adult patients treated for acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL). Most reports focus on osteonecrosis of the hips and/or knees, as impairments in these joints impart significant functional morbidity both during therapy and years following successful cure. [1] [2] [3] [4] Despite the fact that glucocorticoid therapy is a systemic exposure in these patients, little literature exists on the prevalence, extent, interventions or long-term outcomes of patients who have developed osteonecrosis of the shoulders.
In contrast to the hips, knees, and ankles, shoulders are normally non-weight-bearing joints. However, in the presence of lower extremity osteonecrosis, the upper extremity joints may become "weight-bearing" in patients for whom crutches or other ambulatory assistive devices are prescribed to assist with management of lower extremity osteonecrosis. Whether such weight-bearing stresses contribute to development or progression of osteonecrosis in the shoulders is not known.
Early identification of osteonecrotic lesions may allow for implementation of interventions to preserve progression of involvement and ameliorate or minimize functional limitations. 5 As little is known about the prevalence or clinical impact of shoulder osteonecrosis, we describe our single-institutional experience in a population of young patients treated for ALL and NHL and report the severity, interventions and long-term outcome of affected shoulders.
METHODS
With approval from the Institutional Review Board, we retrospectively searched institutional databases from January 1996 through October 2014 for patients under active treatment or with a history of treatment that included dexamethasone, who presented with shoulder pain and who underwent shoulder imaging to evaluate for osteonecrosis. We abstracted demographic information, primary diagnosis, physical function data, and type (if any) of surgical intervention.
Imaging
If there was obvious radiographic evidence of osteonecrosis and/or flattening of the articular surface of the capital humeral epiphysis/humeral head, magnetic resonance imaging (MRI) was considered versus following the patient with radiographs. If radiographs were normal, an MRI was performed. MRIs comprised noncontrast short tau inversion recovery and T1-weighted sequences in the coronal plane and sagittal fast low angle shot (FLASH) images. All imaging was reviewed by a single senior pediatric radiologist who recorded presence or absence of osteonecrosis involving the proximal humerus, estimated the degree of involvement (Z or < 30% of the humeral head articular surface), patency of the proximal humeral physis (as an indicator of skeletal maturity), and distribution of involvement of osteonecrosis (epiphysis, metaphysis, and diaphysis).
Function
Patients were evaluated in orthopaedic clinic to determine upper extremity osteonecrosis, range of motion, pain level and overall function. We used these results to classify function according to the Musculoskeletal and Connective Tissue Disorders category of the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 6, 7 (Table 1) ; higher grades indicate greater impairment. Patients without the adverse event were given a score of 0. Grades were assigned for the initial functional assessment for all patients, for the postprocedure functional assessment for those who required surgical intervention and for the date of last contact.
Medical Management
Patients diagnosed with osteonecrosis who had a full range of motion and were asymptomatic were closely monitored with radiographic and clinical follow-up. Physical therapy was initiated for patients with limited range of motion. Patients who complained of mild to moderate pain received anti-inflammatory agents at the discretion of the medical oncologist. Patients who developed progressively worsening pain and/or loss of motion underwent intra-articular administration of anesthetic and DepoMedrol and physical therapy as the first intervention. Patients failing conservative treatment (anti-inflammatory agents where appropriate, cortisone injections, and physical therapy) underwent surgical intervention.
Surgical Management
Initial surgical management consisted of arthroscopic evaluation. If the cartilage was intact, core decompression was performed. Using fluoroscopic guidance to locate the area of osteonecrosis previously mapped with magnetic resonance (MR), stab incisions were made to access the necrotic area of the proximal humerus. A 3.2 drill bit was advanced through the incision into the necrotic section; multiple perforations with the bit were made until a thorough decompression was achieved. No bone grafting was utilized.
If a significant cartilage defect was found, an attempt was made at pick arthroplasty, debridement, or chondroplasty of the area up to a size of 1 to 2 cm. For lesions larger than 2 cm or if there was complete loss of cartilage and bone was exposed, conservative measures were implemented with plans to perform a resurfacing hemiarthroplasty at a later date. For patients with significant collapse and pain and who were not candidates for arthroscopy, we proceeded directly to resurfacing once the patient's pain and/or motion failed conservative treatment.
Patients who progressed radiographically with further collapse, who developed significant pain and loss of function, or who failed core decompression underwent hemiarthroplasty. The resurfacing technique utilized a standard anterior approach through the deltopectoral complex, reflecting the subscapularis muscle off of the anterior shoulder to allow access into the shoulder joint. Once the shoulder was dislocated, the area of cartilaginous defect was identified, sized and then the appropriate resurfacing hemiarthroplasty was either press-fit or cemented into place based on the patient's bone quality.
RESULTS
Thirty-five patients underwent shoulder MRs between January 1996 and October 2014 and had imaging available on the picture archiving computer system. Imaging was prompted in 24 patients by the onset of shoulder pain. In 2 patients, the initial MR was protocol specified.
Patient Demographics
The study cohort included 22 females and was a median age at cancer diagnosis of 14.2 (range, 4.3 to 19) years. Median age at osteonecrosis diagnosis was 16.7 (range, 5.5 to 28) years. Median time to last follow-up from diagnosis of primary malignancy was 6.4 (range, 0 to 12.7) years and from the diagnosis of osteonecrosis, 4.0 (range, 0 to 8.9) years.
All patients had been or were receiving glucocorticoid-based therapy for ALL or NHL, according to contemporary Institutional Review Board-approved institutional Total Therapy protocols. [8] [9] [10] [11] [12] Twelve patients were treated on Total Therapy XVI, 9 on Total Therapy XV, 13 1 on Total Therapy XIV, 10,11 and 8 on Total Therapy XIIIB, 9,11,12 1 on HLHR13, 14 1 on NHL13, 15 2 on NHL16 16 and 1 on ALL-R16 protocol. 17 All patients are alive a median of 6.8 (range, 0.6 to 21.9) years from diagnosis of ALL/NHL and a median of 4.9 (range, 4.9 to 18.8) years from demonstration of osteonecrosis. Thus, the 35 patients included in our study, represent B2.4% of the cumulative enrolled 1478 patients from the treatment protocols listed above. Twenty-six had a documented history of crutch use for lower extremity osteonecrosis; 9 patients had no record of crutch use.
MR Findings
Of the 35 patients, 22 had MR-defined osteonecrosis in 43 shoulders that involved at least 30% of the articular surface of the capital humeral epiphyses/humeral heads. Nineteen shoulders had <30% involvement of the articular surfaces, 6 shoulders were normal and 2 shoulders were not imaged. Twenty-nine patients had osteonecrosis involving both shoulders. All patients had documented multifocal osteonecrosis of lower extremity joints. The diagnosis of shoulder osteonecrosis preceded that of lower extremity joints in 4 patients by a median of 5.5 years (range, 1.8 to 7.8 y). The demonstration of shoulder osteonecrosis was made simultaneously with that of the lower extremities in 6 patients; for the remaining patients, shoulder osteonecrosis was demonstrated a median of 1.2 years after that of lower extremities (range, 0 to 7.4 y). Fifteen patients (28 shoulders) had no subchondral crescent formation or humeral head collapse.
Surgical Interventions
Eleven patients underwent intra-articular injections for shoulder pain. Of these, 7 shoulders were relieved of symptoms and no further treatment was performed (Table 2). Seven patients (12 shoulders) underwent core decompression; 3 after failing injection, 7 as a primary treatment modality. Nine shoulders received no further treatment after the core decompression. Six patients (8 shoulders) underwent hemiarthroplasty after failure of either injections (3 shoulders) or core decompression (3 shoulders; Fig. 1 ). Two patients (2 shoulders) underwent hemiarthoplasty as a primary treatment without prior injection or core decompression. None underwent total shoulder arthroplasty. Four patients were receiving therapy at the time of the orthopaedic intervention; 2 patients received intra-articular steroid injection and 2 underwent core decompression. All other procedures were performed after completion of therapy (Table 3) .
Joint Functional Outcomes
CTCAE mean scores for initial assessments of 55 shoulders (29 patients) showed moderate negative impact of osteonecrosis on activity of daily living (1.94), decreased ROM limiting athletic activity (0.98), and mild to moderate levels of pain (1.38) ( Table 2 ). Analysis of this group's most recent assessment showed improvement in pain and osteonecrosis over time, with an average pain grade of 0.58 indicating no pain to mild pain, and 1.37 for osteonecrosis grade, indicating asymptomatic to mildly symptomatic impact on activities of daily living. Results also showed minimally worse average ROM grades (1.11). An overall similar pattern of assessments was seen in patients not undergoing orthopaedic intervention (Table 4) .
Ten patients (13 shoulders) underwent intra-articular injection and presented with mean grades indicating moderate to severe grades of osteonecrosis impact (2.61), ROM (2.15), and pain (2.69). Postinjection results indicated improvements in pain (1.23), ROM limitations (1.69), and impact of osteonecrosis (1.76) grades. Seven patients (12 shoulders) underwent core decompression and presented with mean grades of moderate to severe pain (2.75) and impact of osteonecrosis (2.91), and ROM limitations of 25% to 50% (2.00). Following core decompression, improvements were demonstrated for pain (1.00) and impact of osteonecrosis (1.66), but not for ROM (2.08). Six patients (8 shoulders) underwent hemiarthroplasty and presented with mean grades of moderate to severe pain (2.87), osteonecrosis (2.75), and ROM limitations of 25% to 50% (2.37). Postoperative averages showed improvements in all 3 outcomes: impact of osteonecrosis (1.75), pain (0.75), and ROM (1.87).
The median interval between first and last functional assessment was 6.2 (range, 0.9 to 8.9) years; 7 patients had only a single assessment. At the time of initial diagnosis, osteonecrosis-related activities of daily living 
DISCUSSION
Previous investigations of skeletal sequelae in pediatric cancer survivors whose treatment included glucocorticoids have largely focused on the development of symptomatic osteonecrosis of the femoral head. 18 Physical limitations and impact on quality of life in such cases are well reported. 19 However, since oncologic chemotherapy has systemic effects, the prevalence and related clinical impact of glucocorticoid exposure on other joints is also warranted. We document the functional status, medical management and joint outcomes among survivors who developed osteonecrosis of the shoulder(s) as a result of therapy. We found that the diagnosis of osteonecrosis may be delayed likely because the shoulders are non-weight-bearing with even advanced involvement tolerated compared with similar extent of involvement in femoral heads. 20, 21 In a recently published study of adult patients (mean age, 39 y; range, 25 to 55 y), diagnosed with symptomatic glucocorticoid-induced osteonecrosis and followed for an average of 15 years, the shoulder was found to be the second most commonly involved joint (140/200 patients; 70%), second only to hip osteonecrosis (100%). 22 Our results were similar, with all patients demonstrating multifocal involvement of the lower extremities. 23 Mieuttunen and colleagues reported on a small (n = 11) pediatric cohort with ALL who underwent whole-body MR for musculoskeletal pain persisting for at least 4 weeks. Nine of the 11 patients were found to have multifocal osteonecrosis; 8 with epiphyseal lesions. All of the proximal humeral epiphyseal lesions involved more than one third of the articular surface and none were symptomatic. 23 At the time of imaging, most patients in our study had moderate to severe shoulder osteonecrosis with moderate to severe pain and limitations in range of motion. For patients who underwent orthopaedic intervention-intra-articular injection, core decompression or hemiarthroplasty-we found a decrease (improvement) in grade of impact of osteonecrosis, range of motion limitations, and severity of pain for all procedures except for range of motion in patients who underwent core decompression. We found that the greatest improvement was in pain grades across all 3 interventions post-procedurally. Impact of osteonecrosis grades improved to a lesser degree across all 3 types of procedures. Range of motion grades improved in the shoulder resurfacing and injection groups, but not in the group receiving core decompression.
Although we found improvement in symptoms related to shoulder osteonecrosis in most patients who underwent orthopaedic intervention, we also found that some patients complained of persistent moderate to severe pain as a result of their osteonecrosis, and over 60% complained of at least minimal pain after orthopaedic intervention. Continued pain is an important finding as chronic pain significantly impacts health related quality of life, and opioid use for the treatment of chronic pain is associated with even lower quality of life scores (SF-36) and higher occurrence of depression. 24 We also found that some patients had moderate to severe ROM limitations that persisted after intervention. This is important as range of motion limitations directly impact ability to perform daily activities such as personal hygiene, eating, drinking, and dressing. 25 Prospective screening for the detection of osteonecrosis, especially screening beyond that of the hips has not been routinely performed, precluding accurate determination of the prevalence and severity of shoulder involvement. Since glucocorticoid-induced osteonecrosis results from systemic exposure to the drug, MR imaging of all joints may be warranted, at least in high-risk (Table 1) was 3-2-3. She underwent bilateral core decompressions 2 months following the imaging. One month postoperatively, her CTCAE functional code was 2-2-1 bilaterally. E and F, Forty-one months after the core decompression, the patient's functional score had deteriorated to 3-2-3. She underwent right-sided hemiarthroplasty 2 months later. Five months after the hemiarthroplasty, her functional scores were 1-1-0 bilaterally. MR indicates magnetic resonance. Our data support the fact that chemotherapy induced osteonecrosis is multifocal, likely impacting not only the hips, knees, and/or ankles, but also the shoulders. Functional limitations in both lower and upper extremities have the potential to result in significant disability. Loss of shoulder function likely interferes with rehabilitation following surgical intervention for lower extremity osteonecrosis, such as hip or knee replacement, when patients must depend on upper extremity strength to use an assistive device for mobility. Patients with shoulders limited by decreased function or pain may have a more difficult rehabilitation process, which could lead to exacerbated shoulder symptoms, and/or poor rehabilitation outcomes following lower extremity surgery. More research into the relationship between upper and lower extremity disease is merited.
Strengths of this study stem from the standardized method of clinical grading of osteonecrosis using the established assessment of CTCAE 4.0, range of motion and severity of pain. Though the management of osteonecrosis varied and was designed on a case-by-case basis, patient management by a single clinical team allowed for excellent characterization of patient status and follow-up.
The results of our report must be considered within the limitations of the retrospective nature of our study which curtailed standardization of patient selection and outcome measures. In addition, the clinical management and surgical interventions evolved over nearly 9 years and likely contributed to nonstandardized surgical techniques. Similarly, therapeutic protocols evolved and glucocorticoid doses varied over the course of the study. Most patients included in this report underwent evaluation of shoulder functionality and imaging due to symptoms that suggested the development of osteonecrosis of the shoulders. Thus, determination of the true prevalence of shoulder osteonecrosis in pediatric patients treated for ALL and NHL is precluded but is part of ongoing clinical research initiatives at our institution. Despite these limitations, we believe our report is clinically valuable and contributes to the understanding of this understudied complication of therapy in pediatric patients.
We know of no preventative measures to protect patients from developing osteonecrosis at this time. However, efforts are being made to identify patients at increased risk for developing ON as early as possible, to allow for possible modifications of therapy to minimize toxicity but without compromising cure. However, understanding the prevalence, severity and distribution of osteonecrosis in children treated for cancer should contribute to developing interventions to minimize and ameliorate this skeletal toxicity. 
